Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | TGM1 | P22735 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358150 | 1.00 | NR1H2 (0.31) | NR1H2NR1H3F13A1TGM2TGM1 | |
| SCHEMBL22968747 | 0.88 | PDE4B (0.31) | NR1H2NR1H3F13A1TGM2TGM1 | |
| SCHEMBL21366944 | 0.88 | NR1H2 (0.32) | NR1H2F13A1TGM2TGM1 | |
| SCHEMBL21367078 | 0.88 | HSD17B10 (0.33) | NR1H2F13A1TGM2TGM1CHRM2 | |
| SCHEMBL21366881 | 0.87 | PDE4B (0.32) | NR1H2NR1H3F13A1TGM2TGM1 | |
| SCHEMBL22968833 | 0.87 | NR1H2 (0.31) | NR1H2NR1H3F13A1TGM2TGM1 | |
| SCHEMBL21358216 | 0.85 | KDM4E (0.32) | — | |
| SCHEMBL31367145 | 0.85 | NR1H2 (0.31) | NR1H2NR1H3F13A1TGM2TGM1 | |
| SCHEMBL31367116 | 0.85 | NR1H2 (0.31) | NR1H2NR1H3F13A1TGM2TGM1 | |
| SCHEMBL31367125 | 0.85 | NR1H2 (0.31) | NR1H2NR1H3F13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215116-B2 | Arginase inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-02-04 | — | — | US | disclosed |
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-02-11 | — | — | US | disclosed |
| WO-2019177873-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | NR1H2 159/4885NR1H3 177/4885F13A1 553/4885 |
| US-12215116-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, PRMT1 | NR1H2 159/4885NR1H3 177/4885F13A1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.